Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial
Key facts
- Who runs it
- Oslo University Hospital
- Where
- Norway7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 150 people, planned
- Started
- 24 Oct 2024
- Expected to end
- Dec 2029
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Methotrexate
- TNF Inhibitor
- Record updated
- 19 October 2026
Who can take part
- Age
- 2 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Participant must be 2-<18 years of age at the time of signing the informed consent
- Fulfilment of the International League of Associations for Rheumatology (ILAR) classification criteria for non-systemic Juvenile Idiopathic Arthritis (JIA)
- Inactive disease for ≥12 months documented at a minimum of 2 consecutive visits and documented inactive disease according to Wallace criteria at inclusion, and no active uveitis for ≥24 months
- Stable treatment with methotrexate and Tumor Necrosis Factor inhibitor (TNFi) for ≥6 months. Weight adjustments permitted
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF)
- Male participants: No contraceptive measures necessary
- Female participants: contraception guidance for women of childbearing potential (WOCP)
Who cannot take part
- Use of oral, intra-articular, intramuscular or intravenous corticosteroids due to JIA less than 12 months prior to randomization
- Drug/alcohol abuse which hampers adherence to the study protocol as based on the investigators judgement
- Chronic widespread pain syndrome
- Major comorbidity including uncontrolled infectious, neurological or mental disease, malignant disease, severe heart failure, severe renal failure, active ulcus ventriculi, and uncontrolled diabetes mellitus
- Any condition that in the view of the investigator would suggest that the patient is unable to comply with the study protocol and procedures
- Participating in an ongoing clinical randomized study
- Language barriers that hamper adherence to the study protocol
- Pregnancy or breastfeeding
- Unwillingness to use safe contraception for sexually active WOCP
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 2 and 17 years old?
This trial is currently available in Norway.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to compare three different maintenance and step-down treatment strategies in children and adolescents with juvenile idiopathic arthritis in sustained remission. The main questions it aims to answer are:
Read full original descriptionShow less
* Is the proportion of study participants with a disease flare different between each of the two drug withdrawal arms and the stable treatment arm during 12 months? * Does the proportion of study participants with a disease flare differ between the two drug withdrawal arms during 12 months? * How long time does it take before a disease flare occurs, and how long does it take before disease remission is reestablished for participants in the different treatment arms?
Participants will be randomized to either A) continued stable treatment with methotrexate and tumor-necrosis alpha inhibitor (TNFi); B) gradual withdrawal of methotrexate while continued stable dose TNFi; or C) gradual withdrawal of TNFi.
Participants will be examined every 4 month, and with extra visits if they experience increased symptoms or suspect a disease flare. If a flare occurs, the medications received at study inclusion will be restarted.
The 3 groups in the trial
- Stable treatmentExisting treatment, for comparison
Stable treatment with methotrexate and TNFi
Treatment: Methotrexate and TNF Inhibitor
- Methotrexate withdrawalTreatment being tested
Gradual withdrawal of methotrexate
Treatment: Methotrexate
- TNFi withdrawalTreatment being tested
Gradual withdrawal of TNFi
Treatment: TNF Inhibitor
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Optimizing Treatment for Children and Adolescents With Juvenile Idiopathic Arthritis in Sustained Remission: a Comparison of Three Treatment Strategies. The MOVE-JIA Trial
- Criteria questions
- Built from NCT06653634, who can take part
- Publications
- Record updated
- 19 October 2026